leisure time -WSS

leisure time

author：hotspot 2025-09-30 16:29:10 - browse：32

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Johnson & Johnson sues to stop Medicare negotiation

leisure time

WSS

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Oak Street deal isn't the answer to health care's woes

BridgeBio heart drug succeeds in pivotal study

Abbott's new stent may help patients with peripheral artery disease

Johnson & Johnson sues to stop Medicare negotiation

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Lack of darker skin in textbooks, journals harms patients of color

Guidelines to prevent youth baseball injuries need more muscle

Why you get paid to donate plasma but not blood

Moonlake's readout produced a cash windfall. Risks remain

WuXi Biologics beefs up its lobbying operation

After affirmative action ruling, medical educators look to 'holistic review'

More hospitals are billing patients as online messages surge

Medical leaders decry Supreme Court decision on affirmative action

More hospitals are billing patients as online messages surge

explore

FDA seeking to stop procedures at two unregulated stem cell clinics

Supreme Court to hear if Covid misinformation is protected speech

Lack of darker skin in textbooks, journals harms patients of color

Obesity drug from Roche shows promise in early study

US soldier in North Korean custody after crossing DMZ line

HHS suspends federal funding for EcoHealth Alliance

leisure time

leisure time

leisure time

knowledge